Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-51. (Canceled)

52. (Currently amended) A method of treating a human subject suffering loss of photoreceptor function and autosomal dominant retinitis pigmentosa due to expression of a mutant human opsin protein with a substitution of Proline 23 by Histidine (P23H mutant opsin protein), said method comprising:

treating loss of photoreceptor function in the human subject by administering to the subject an effective amount of a synthetic retinoid that is 9-*cis*-12-methyl retinal ~~a derivative of 9-*cis* retinal, wherein said derivative is capable of inducing the *in vivo* folding and stabilization of a P23H mutant opsin protein to form visual pigment after intraocular injection into an eye of a transgenic mouse expressing the human P23H mutant opsin protein~~,

wherein the human subject has autosomal dominant retinitis pigmentosa due to expression of the P23H mutant opsin protein.

53. (Canceled)

54. (Previously presented) The method of claim 52, wherein the synthetic retinoid is in a pharmaceutically acceptable vehicle.

55. (Previously presented) The method of claim 52, wherein the synthetic retinoid is orally administered to the human subject.

56. (Previously presented) The method of claim 52, wherein the synthetic retinoid is locally administered to the human subject.

57. (Previously presented) The method of claim 56, wherein the synthetic retinoid is locally administered by eye drops.

58. (Previously presented) The method of claim 56, wherein the synthetic retinoid is locally administered by intraocular injection.

59. (Previously presented) The method of claim 56, wherein the synthetic retinoid is locally administered by periocular injection.

60. (Previously presented) The method of claim 52, wherein the subject endogenously forms rhodopsin, from opsin and endogenous 11-*cis*-retinal, as a visual pigment.

61. (Currently amended) [[he] The method of claim 56, wherein the subject endogenously forms rhodopsin, from opsin and endogenous 11-*cis*-retinal, as a visual pigment.

62. (Previously presented) The method of claim 52, further comprising identifying the subject as expressing a P23H mutant opsin protein before said administering.

63-71. (Canceled).